A5021092653- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Rheumatoid Arthritis Research and Therapies
- Traffic and Road Safety
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Cytokine Signaling Pathways and Interactions
- Amyotrophic Lateral Sclerosis Research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- T-cell and B-cell Immunology
- Neurogenesis and neuroplasticity mechanisms
- Autoimmune and Inflammatory Disorders Research
- Skin and Cellular Biology Research
- Human-Automation Interaction and Safety
- Systemic Sclerosis and Related Diseases
- Safety Warnings and Signage
- Impact of Light on Environment and Health
- Mesenchymal stem cell research
- Fungal Plant Pathogen Control
- Immune Response and Inflammation
- CNS Lymphoma Diagnosis and Treatment
- Mycobacterium research and diagnosis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Ottawa Hospital
2016-2025
University of Ottawa
2016-2025
Ottawa Hospital Research Institute
2016-2025
Heinrich Heine University Düsseldorf
2011-2024
Düsseldorf University Hospital
2011-2024
Palacký University Olomouc
2024
The University of Western Australia
2024
Inserm
2024
Université de Bordeaux
2024
The University of Sydney
2024
Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity relapsing-remitting multiple sclerosis (MS). We evaluated rituximab adults with primary progressive MS (PPMS) through 96 weeks and safety 122 weeks.Using 2:1 randomization, 439 PPMS patients received two 1,000 mg intravenous or placebo infusions every 24 weeks, (4 courses). The endpoint was time to confirmed progression (CDP), prespecified increase Expanded Disability...
Abstract Although recent animal studies have fuelled growing interest in Ab-independent functions of B cells, relatively little is known about how human cells and their subsets may contribute to the regulation immune responses either health or disease. In this study, we first confirm that effector cytokine production by normal context dependent demonstrate involves reciprocal proinflammatory anti-inflammatory cytokines. We further report network dysregulated patients with autoimmune disease...
Abstract Objective To determine to what degree changes in retinal nerve fiber layer (RNFL) thickness after optic neuritis (ON) correlate with either visual recovery or impairment. Methods ON can cause visible defects within the RNFL, which be quantified using optical coherence tomography (OCT). It may possible predict by measuring RNFL loss ON. Fifty‐four patients underwent repeated evaluations and standardized ophthalmic testing Regression analyses were used relationship between function....
New criteria for the diagnosis of multiple sclerosis (MS) were published as result an internationally formed committee. To increase specificity and to minimize number false diagnoses, committee recommended use both clinical paraclinical criteria, latter involving information obtained from magnetic resonance imaging, evoked potentials, cerebrospinal fluid (CSF) analysis. Although rigorous imaging requirements provided, “new paper” fell short in terms guidelines how CSF analysis should be...
Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in aggressive forms of multiple sclerosis (MS) that fail to respond standard therapies.To evaluate the long-term outcomes patients who underwent AHSCT for treatment MS a large multicenter cohort.Data were obtained multicenter, observational, retrospective cohort study. Eligibility criteria receipt between January 1995 and December 2006 availability prespecified minimum data set comprising disease subtype at baseline;...
On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces risk conversion from first demyelinating event (also known as clinically isolated syndrome) multiple sclerosis. During period January 2009 through July 2013, randomly assigned participants who had their symptoms within previous 180 days receive either 100 mg minocycline, administered orally twice daily, or placebo. Administration placebo was continued until...
Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There now substantial evidence for this to be used alongside magnetic resonance imaging (MRI) clinical measures of disease progression as decision-making tool the management patients with MS. Serum NfL (sNfL) has certain advantages over traditional MS such MRI because it relatively noninvasive, inexpensive,...
Importance Biomarkers distinguishing nonrelapsing progressive disease biology from relapsing in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an accessible that most closely reflects central nervous system biology. Objective To identify CSF biological measures associated with MS pathobiology. Design, Setting, and Participants This cohort study assessed data 2 prospective cohorts: a test provided serial CSF, clinical, imaging assessments multicenter of patients (RMS) or...
Reactive gliosis is a characteristic response of astrocytes to inflammation and trauma the central nervous system. To investigate whether soluble factors (cytokines) from inflammatory mononuclear cells that accumulate at lesion sites can provide cellular signals initiate identify such cytokines, we have tested found supernatants derived subsets activated human T lymphocytes (CD8+ or CD4+) are potent mitogens for cultured adult astrocytes. This effect blocked by neutralizing antibody...
Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based may provide a new strategy bolstering regeneration and through neuro-axonal protection or remyelination. Mesenchymal stem cells modulate pathological responses experimental autoimmune encephalitis, alleviating disease, also stimulate system release soluble factors. Autologous allogeneic mesenchymal have been safely administered...
Abstract Objective To assess demyelination and remyelination in vivo acute gadolinium (Gd)‐enhancing lesions of multiple sclerosis (MS). Methods We measured significant changes magnetization transfer ratio (MTR) consistent with individual lesion voxels, as well the mean normalized MTR over all voxels during after contrast enhancement, MS patients participating a 3‐year Canadian trial assessing immunoablation autologous stem cell transplantation for treatment MS. Results The average exhibited...
<b>Background: </b> Immunomodulatory therapies are widely used in adults with multiple sclerosis (MS) and safety tolerability is well-established. Although at least 5% of all patients MS experience the clinical onset their disease prior to age 18 years, available literature on immunomodulatory for pediatric-onset limited. <b>Methods: The authors retrospectively reviewed interferon beta-1b (IFNβ-1b) a cohort 43 children adolescents treated mean 29.2 months (SD 22.3 months). <b>Results: Mean...
To define changes in phenotype and functional responses of reconstituting T cells patients with aggressive multiple sclerosis (MS) treated ablative chemotherapy autologous hematopoietic stem cell transplantation (HSCT).Clinical brain magnetic resonance imaging measures disease activity were monitored serially participating the Canadian MS HSCT Study. Reconstitution kinetics immune-cell subsets determined by flow cytometry, whereas thymic function was assessed using T-cell receptor excision...
Teriflunomide, an oral disease-modifying therapy in development for patients with relapsing forms of multiple sclerosis (RMS), was well tolerated and effective reducing magnetic resonance imaging (MRI) lesions 179 RMS a phase 2 36-week, placebo-controlled study.A total 147 who completed the core study entered open-label extension. Teriflunomide continued their assigned dose, placebo were re-allocated to teriflunomide, 7 mg/day or 14 mg/day. An interim analysis performed at cut-off on January...
<h3>Objective:</h3> To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA) haplotype DR2 or DR4 (DR2<sup>+</sup> DR4<sup>+</sup>). <h3>Methods:</h3> This multicenter randomized 2-year, double-blind, placebo-controlled study included 612 a diagnosis SPMS an Expanded Disability Status Scale (EDSS) score 3.5–6.5, stratified according to baseline EDSS (3.5–5.0, 5.5–6.5) HLA DR4<sup>+</sup>,...